Trials / Recruiting
RecruitingNCT06383871
A Phase I Clinical Study of HRS-7058 in Patients With Advanced Malignant Tumour
An Open, Multicenter Phase I Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of HRS-7058 Monotherapy in Patients With Advanced Solid Tumour With KRAS G12C Mutation
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 233 (estimated)
- Sponsor
- Shandong Suncadia Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multicentre, open phase I clinical study of dose escalation, dose extension and efficacy extension of HRS-7058 in subjects with advanced malignant tumour. To evaluate the safety, tolerability, pharmacokinetics and efficacy of HRS-7058.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS-7058 capsule/ HRS-7058 tablet | HRS-7058 capsule/ HRS-7058 tablet |
Timeline
- Start date
- 2024-06-06
- Primary completion
- 2026-06-01
- Completion
- 2026-06-01
- First posted
- 2024-04-25
- Last updated
- 2026-01-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06383871. Inclusion in this directory is not an endorsement.